Dose Finding and Reactogenicity of Reduced-dose Intradermal Administration of Two Quadrivalent Meningococcal Conjugate Vaccines (Menveo and Nimenrix) in Healthy Adults (MENID-1)
Latest Information Update: 24 May 2018
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
- Focus Pharmacodynamics
- 16 May 2018 Results (n=12) assessing immunogenicity and tolerability of escalating doses of two different formulations of meningococcal vaccine groups A-C-Y-W-135 conjugate (Menveo versus Nimenrix) for the prevention of meningococcal groups A, C, W-135 and Y infections in volunteers, were published in the Vaccine.
- 08 Feb 2013 New trial record